| Name | Title | Contact Details |
|---|
MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients. In addition, MannKind is applying our novel technologies and services to support partner development efforts.
Metavention is a venture-backed medical device company founded in 2012 that is developing a novel glucose control therapy for patients with type 2 diabetes. Metabolic Neuromodulation Therapy (MNT) is a simple cardiovascular procedure intended to modulate sympathetic nervous system activity in patients with Type 2 diabetes for the purpose of lowering blood glucose levels. MNT was developed based on published scientific data and extensive animal studies suggesting a link between elevated sympathetic nerve activity in the metabolic system and increased levels of blood glucose. MNT is currently being studied in human clinical trials and represents a potentially important new treatment option for patients with Type 2 Diabetes.
We are working to methodically engineer durable gene therapies for people with devastating diseases.
Chart is a recognized global brand for the design and manufacture of highly engineered cryogenic equipment used from the beginning to the end in the liquid gas supply chain.
EcoSynthetix is a Lansing, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.